Drug Profile
Research programme: advanced glycosylation end product receptor antagonists - Medifron
Alternative Names: MDR-066; RAGE antagonists - MedifronLatest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Medifron DBT
- Class
- Mechanism of Action Advanced glycosylation end product receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 16 Jun 2022 Preclinical development in Alzheimer's-disease is still ongoing in South Korea
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea
- 31 Jul 2016 Preclinical trials in Alzheimer's disease in South Korea (unspecified route)